$56.8 B

CELG Mkt cap, 11-Oct-2018

$7.4 B

Celgene Revenue Q2, 2018
Celgene Gross profit (Q2, 2018)7.1 B
Celgene Gross profit margin (Q2, 2018), %96.4%
Celgene Net income (Q2, 2018)1.9 B
Celgene EBIT (Q2, 2018)1.7 B
Celgene Cash, 30-Jun-20181.5 B
Celgene EV56.8 B

Celgene Revenue

Celgene revenue was $13 b in FY, 2017

Embed Graph

Celgene Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

6.5b7.7b9.3b11.2b13.0b

Revenue growth, %

18%21%21%

Cost of goods sold

340.4m385.9m420.1m438.0m461.0m

Gross profit

6.2b7.3b8.8b10.8b12.5b

Gross profit Margin, %

95%95%95%96%96%

R&D expense

5.9b

General and administrative expense

2.9b

Operating expense total

8.3b

EBIT

1.8b2.5b2.3b3.2b4.7b

EBIT margin, %

28%33%24%28%36%

Interest expense

91.6m176.1m310.6m500.1m

Pre tax profit

1.7b2.3b2.0b2.4b4.3b

Income tax expense

215.5m327.5m421.5m373.3m1.4b

Net Income

1.4b2.0b1.6b2.0b2.9b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.3b2.3b2.5b2.8b3.0b3.0b3.3b3.3b3.5b7.4b

Cost of goods sold

100.8m109.9m105.9m110.9m107.7m113.0m111.0m118.0m135.0m261.0m

Gross profit

2.2b2.2b2.4b2.6b2.9b2.8b3.2b3.2b3.4b7.1b

Gross profit Margin, %

96%95%96%96%96%96%97%96%96%96%

R&D expense

1.1b1.3b733.2m948.7m1.7b995.0m835.0m1.3b2.2b3.5b

General and administrative expense

616.8m550.3m543.0m732.1m698.0m620.0m939.0m608.0m864.0m1.7b

Operating expense total

1.9b2.3b1.5b1.9b2.6b1.8b2.0b2.2b3.3b5.6b

EBIT

415.8m79.6m1.0b823.7m411.5m1.1b1.3b1.1b218.0m1.7b

EBIT margin, %

18%3%40%30%14%38%40%33%6%23%

Interest expense

48.3m88.5m121.9m123.3m127.8m127.0m126.0m127.0m166.0m358.0m

Pre tax profit

470.8m(19.9m)921.6m695.1m256.8m1.0b1.1b991.0m1.0b2.3b

Income tax expense

114.6m14.2m120.9m96.9m85.4m84.0m69.0m3.0m184.0m446.0m

Net Income

372.5m279.7m597.8m508.5m718.9m356.2m(34.1m)800.7m598.2m171.4m941.0m1.1b988.0m846.0m1.9b

Celgene Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

3.2b4.1b4.9b6.2b7.0b

Inventories

340.4m393.1m443.4m497.9m541.0m

Current Assets

7.6b9.7b9.4b10.9b14.9b

PP&E

593.4m642.6m814.1m929.8m1.1b

Goodwill

2.0b2.2b4.9b4.9b4.9b

Total Assets

13.4b17.3b27.1b28.1b30.1b

Accounts Payable

156.2m198.2m240.8m247.1m305.0m

Short-term debt

544.8m605.9m500.7m

Current Liabilities

1.9b2.1b2.0b3.0b3.0b

Long-term debt

Total Debt

544.8m605.9m500.7m

Total Liabilities

23.2b

Additional Paid-in Capital

8.7b9.8b11.1b12.4b13.8b

Retained Earnings

4.5b6.5b8.1b10.1b13.1b

Total Equity

5.6b6.5b5.9b6.6b6.9b

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

2.4 x2.7 x4.6 x4.3 x4.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

2.4b2.4b3.2b3.7b4.4b4.5b6.0b4.4b5.1b5.5b5.3b6.7b5.5b2.8b1.5b

Inventories

313.3m347.8m360.0m372.0m386.7m414.3m420.9m470.6m490.4m507.9m509.0m533.0m537.0m536.0m555.0m

Current Assets

7.6b6.9b8.1b8.8b9.7b9.9b10.2b8.4b9.2b9.6b11.6b13.1b14.8b7.9b6.9b

PP&E

592.3m595.7m605.1m623.6m649.7m675.2m702.0m840.0m854.0m891.3m958.0m989.0m1.0b1.3b1.3b

Goodwill

2.0b2.0b2.2b2.2b2.2b2.2b4.7b4.9b4.9b4.9b4.9b4.9b4.9b8.0b8.0b

Total Assets

13.6b12.7b15.6b16.4b17.5b17.7b27.4b26.0b26.6b26.8b28.8b30.3b31.7b34.6b33.4b

Accounts Payable

139.6m149.4m184.5m196.7m204.0m204.9m189.4m219.7m229.8m235.4m240.0m272.0m263.0m320.0m294.0m

Short-term debt

405.9m869.8m192.3m100.0m504.4m1.4b1.2b501.0m500.0m500.0m1.4b1.5b

Current Liabilities

1.9b2.4b1.5b1.4b2.1b3.0b3.1b1.8b2.0b2.6b2.6b3.2b4.0b3.1b4.5b

Total Debt

405.9m869.8m192.3m100.0m504.4m1.4b1.2b501.0m500.0m500.0m1.4b1.5b

Total Liabilities

7.7b8.2b10.8b10.6b10.7b11.4b22.0b20.9b21.0b21.1b21.2b21.9b21.9b29.4b30.0b

Additional Paid-in Capital

8.5b8.9b9.2b9.4b10.2b10.5b10.8b11.4b11.7b12.0b12.7b13.2b13.6b14.1b13.8b

Retained Earnings

4.3b4.8b5.4b5.9b7.2b7.5b7.5b8.9b9.5b9.6b11.0b12.1b13.1b14.4b15.4b

Total Equity

6.3b5.4b5.1b5.5b5.7b7.6b8.4b9.9b5.2b3.4b

Financial Leverage

2.8 x5.1 x5.1 x4.8 x4.7 x3.8 x3.6 x3.2 x6.7 x9.8 x

Celgene Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.4b2.0b1.6b2.0b2.9b

Depreciation and Amortization

134.0m

Accounts Receivable

(101.4m)(166.3m)(304.7m)(222.4m)(236.0m)

Inventories

(89.7m)(56.5m)(50.6m)(55.3m)(42.0m)

Cash From Operating Activities

2.2b2.8b2.5b4.0b5.2b

Cash From Investing Activities

(528.6m)(1.4b)(6.3b)(1.0b)(2.9b)

Long-term Borrowings

(513.9m)(1.9b)

Cash From Financing Activities

(553.7m)(417.4m)4.6b(1.6b)(1.6b)

Interest Paid

90.8m196.2m243.3m527.2m539.0m

Income Taxes Paid

291.9m294.6m361.1m373.0m475.0m

Free Cash Flow

2.3b3.0b2.8b4.2b5.0b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

1.2b279.7m877.5m1.4b718.9m1.1b1.0b800.7m1.4b1.6b941.0m2.0b3.0b846.0m1.9b

Depreciation and Amortization

71.8m25.5m52.1m78.1m28.1m57.8m86.6m29.2m58.5m89.6m32.0m66.0m100.0m126.0m296.0m

Accounts Receivable

(138.7m)(9.8m)(61.8m)(46.0m)(59.5m)(140.9m)(145.8m)23.1m(80.7m)(143.8m)17.0m(75.0m)(139.0m)(47.0m)(157.0m)

Inventories

(62.6m)(7.0m)(19.1m)(33.6m)7.3m(19.2m)(27.1m)(25.6m)(45.2m)(62.3m)(10.0m)(32.0m)(37.0m)6.0m(14.0m)

Cash From Operating Activities

1.7b557.1m1.1b2.0b856.5m1.1b1.4b974.9m1.9b2.6b853.0m2.5b3.6b(325.0m)904.0m

Cash From Investing Activities

(1.4b)(220.1m)(1.2b)(1.4b)338.0m239.7m(5.9b)(110.2m)(185.6m)(298.0m)(1.7b)(1.6b)(4.0b)(5.7b)(5.8b)

Cash From Financing Activities

103.7m(1.2b)110.0m(65.9m)(908.1m)(951.3m)6.4b(1.3b)(1.5b)(1.7b)1.8b(643.0m)

Interest Paid

67.4m52.2m75.9m126.2m50.2m120.2m171.1m200.9m264.8m463.3m198.0m262.0m461.0m190.0m300.0m

Income Taxes Paid

226.2m96.6m193.4m275.0m106.7m247.2m345.6m102.1m227.1m345.1m128.0m333.0m450.0m387.0m786.0m

Free Cash Flow

1.6b532.4m1.0b1.9b814.2m1.0b1.3b915.3m1.8b2.5b791.0m2.3b3.4b(413.0m)736.0m

Celgene Ratios

USDY, 2018

EV/EBIT

33.3 x

EV/CFO

62.8 x

EV/FCF

77.1 x

Financial Leverage

9.8 x
Report incorrect company information

Celgene Operating Metrics

FY, 2016

Active Clinical Studies

52
Report incorrect company information